Free Trial
NYSE:ENZ

Enzo Biochem (ENZ) Stock Price, News & Analysis

Enzo Biochem logo
$0.98 -0.01 (-0.72%)
(As of 03:08 PM ET)

About Enzo Biochem Stock (NYSE:ENZ)

Key Stats

Today's Range
$0.98
$1.02
50-Day Range
$0.99
$1.17
52-Week Range
$0.97
$1.50
Volume
141,706 shs
Average Volume
99,108 shs
Market Capitalization
$51.20 million
P/E Ratio
N/A
Dividend Yield
40.82%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Enzo Biochem Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
10th Percentile Overall Score

ENZ MarketRank™: 

Enzo Biochem scored higher than 10% of companies evaluated by MarketBeat, and ranked 921st out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Enzo Biochem.

  • Percentage of Shares Shorted

    1.31% of the float of Enzo Biochem has been sold short.
  • Short Interest Ratio / Days to Cover

    Enzo Biochem has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Enzo Biochem has recently decreased by 4.56%, indicating that investor sentiment is improving.
  • Dividend Leadership

    Enzo Biochem is a leading dividend payer. It pays a dividend yield of 39.60%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Enzo Biochem does not have a long track record of dividend growth.

  • Read more about Enzo Biochem's dividend.
  • Percentage of Shares Shorted

    1.31% of the float of Enzo Biochem has been sold short.
  • Short Interest Ratio / Days to Cover

    Enzo Biochem has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Enzo Biochem has recently decreased by 4.56%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Enzo Biochem this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for ENZ on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Enzo Biochem insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.50% of the stock of Enzo Biochem is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 36.90% of the stock of Enzo Biochem is held by institutions.

  • Read more about Enzo Biochem's insider trading history.
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Stock News Headlines

Enzo Biochem (NYSE:ENZ) Stock, Option Chain
917 Trades… Zero Losses?
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
Enzo Biochem Reports Revenue Growth Despite Losses
See More Headlines

ENZ Stock Analysis - Frequently Asked Questions

Enzo Biochem's stock was trading at $1.39 at the beginning of the year. Since then, ENZ shares have decreased by 27.0% and is now trading at $1.0150.
View the best growth stocks for 2024 here
.

Enzo Biochem, Inc. (NYSE:ENZ) posted its quarterly earnings results on Tuesday, October, 15th. The medical research company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. The medical research company had revenue of $20.92 million for the quarter. Enzo Biochem had a negative trailing twelve-month return on equity of 11.84% and a negative net margin of 81.73%.

Top institutional investors of Enzo Biochem include Geode Capital Management LLC (0.71%) and BBR Partners LLC (0.19%). Insiders that own company stock include James G Wolf, Hamid Erfanian, David Bench and Kara Cannon.
View institutional ownership trends
.

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzo Biochem investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and OneLife Technologies (OLMM).

Company Calendar

Last Earnings
10/15/2019
Ex-Dividend for 12/2 Dividend
11/15/2024
Today
11/21/2024
Dividend Payable
12/02/2024
Next Earnings (Estimated)
12/20/2024
Fiscal Year End
7/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Employees
520
Year Founded
1976

Profitability

Net Income
$-26,080,000.00
Pretax Margin
-30.77%

Debt

Sales & Book Value

Annual Sales
$31.91 million
Book Value
$1.09 per share

Miscellaneous

Free Float
44,146,000
Market Cap
$52.52 million
Optionable
Optionable
Beta
0.73

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NYSE:ENZ) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners